
Eli Lilly (LLY) Stock Forecast & Price Target
Eli Lilly (LLY) Analyst Ratings
Bulls say
Eli Lilly is a strong company with a diverse portfolio of products in key therapeutic areas such as oncology, cardiometabolic, and immunology, providing a solid foundation for future revenue growth. The recent negative news regarding an adverse event reported to FDA's FAERS database is seen as temporary and unrelated to one of its key drugs, Foundayo. With strong projected revenue and EPS growth over the next few years, Eli Lilly presents a compelling investment opportunity for investors seeking exposure to the pharmaceutical industry.
Bears say
Eli Lilly is facing significant headwinds in their key products, with potential pricing pressure and competition in the cardiometabolic market from Tirzepatide and Forglipron. The outlook for their oncology drugs is also uncertain, with limited potential for sales growth in a highly competitive and evolving market. Furthermore, their pipeline products may not perform as expected, posing a risk to future revenue and earnings.
This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.
Eli Lilly (LLY) Analyst Forecast & Price Prediction
Start investing in Eli Lilly (LLY)
Order type
Buy in
Order amount
Est. shares
0 shares